AmerisourceBergen: The Extra Drug Became Another Sale

In the AmerisourceBergen oncology overfill settlement, the company agreed in October 2018 to pay $625 million to resolve civil allegations of improper repackaging, double billing and physician kickbacks. Extra drug included in a vial to help deliver the labeled dose allegedly became material for additional syringes, additional sales and a financial inducement to the doctors buying them. For someone inside oncology distribution, the connection between the production floor, the customer discount and the government claim is the heart of this case.

This pharmaceutical fraud case concerned oncology-supportive medicines distributed to physicians treating cancer patients. The business sat between the original drug manufacturer and the practice administering the drug, with an opportunity to change both the package and the economics before the patient received it.

How the Oncology Syringe Program Worked

AmerisourceBergen’s operation allegedly bought manufacturers’ vials, extracted their contents and sold the drug back into oncology practices as prefilled syringes. The whistleblower’s first amended complaint describes the physical transactions inside that business, including a repackaging facility in Dothan, Alabama.

According to the complaint, Oncology Supply Company bought the vials from manufacturers and sold them to Medical Initiatives, which operated at Oncology Supply’s distribution center. Medical Initiatives allegedly made the syringes and sold them back to Oncology Supply for sale to physician customers. That is the drug and money flow the complaint alleged: the medicine moved through a repackager before reaching the practice, while purchases and sales passed between businesses under common ownership.

Both businesses belonged to AmerisourceBergen. The purchasing organization International Oncology Network supplied another part of the commercial arrangement by negotiating drug contracts for physician members.

The government’s settlement summary names Procrit, Aloxi, Kytril and its generic form granisetron, Anzemet and Neupogen. The complaint described nausea and vomiting treatments among the repackaged drugs, along with Procrit for chemotherapy-related anemia.

Overfill explains the production opportunity. As the complaint explains it, a small amount of liquid can remain in the vial or syringe when a dose is withdrawn and administered. Manufacturers include extra drug so the provider can deliver the full labeled amount. The allegation was that Medical Initiatives used centrifuge and vacuum equipment to extract that extra drug along with the rest of the contents and turn it into saleable syringe inventory.

Why Overfill Became a Billing Problem

Overfill allegedly created extra revenue because the operation sold drug that had arrived in the original vial at no additional charge. The civil settlement included a double-billing allegation. The government alleged that harvesting the overfill let the company create more doses than it bought from the manufacturers and bill more than one provider for the same vial, causing some of those providers to bill federal health care programs for the same vial more than once. The complaint also describes how free product could reach a government claim through a purchased syringe.

In that account, Oncology Supply sold the physician a syringe containing the labeled dose. The physician administered it and billed an insurer such as Medicare. Looking only at the physician’s purchase, there was an invoice for a syringe. Looking back through the repackaging operation, some of the product came from the free overfill in manufacturers’ vials. The complaint alleged that the sale through Medical Initiatives and Oncology Supply obscured that origin.

Medicare’s Part B payment rule makes the distinction consequential: additional product in a vial does not represent a cost to providers and is not incorporated into the average sales price payment limit. The complaint cited Medicare’s policy against paying for harvested overfill, including amounts pooled from multiple containers. Turning the excess into a new package was the alleged bridge between free product and a paid claim.

There was a price-reporting allegation too. The complaint alleged that Medical Initiatives submitted no average sales price information for the syringes it produced. The whistleblower said the missing reports kept the lower price created by the overfill operation from reaching Medicare’s reimbursement calculation. The connection to average sales price reporting therefore ran beyond the individual practice’s bill: the complaint challenged what the repackager failed to report about its own sales.

For an insider, those are different records of the same business. Production quantities show what came out of the vials. Sales records show what the practice bought. Price reports and claims show what the public program was told. The alleged profit becomes much easier to understand when those records sit beside each other.

The Physician Discount and the Purchasing Fee

The alleged physician kickback was a share of the overfill benefit, delivered through the price of the syringe. A lower purchase price gave the practice a reason to choose the syringe program and retain more of the reimbursement. The settlement itself resolved allegations that AmerisourceBergen gave physicians kickbacks to buy Procrit through the syringe program, in the form of general pharmacy credits that the invoice did not identify as specific to Procrit. The government also alleged that the scheme let the company offer product discounts to win new customers and keep existing ones buying its entire portfolio of oncology drugs.

The complaint illustrates the incentive with an example in which extraction produced a price advantage for Oncology Supply. In that example, the distributor shared the benefit with the physician, while the purchasing organization could earn a fee on the sale:

The extra liquid allegedly supported a sale for the distributor, a discount for the physician and an administration fee for the purchasing organization. The complaint alleged that government health care programs, including Medicare and Medicaid, then reimbursed physicians for the free product. Taxpayers paid at the end of a chain that began with drug the manufacturer supplied at no additional charge.

The complaint also alleged that manufacturer fees influenced which competing drugs ION promoted. Where drugs faced competition, it said, ION could favor the manufacturer paying the higher administration fee by offering physicians discounts on that manufacturer’s product.

Common ownership made those payments especially important. According to the complaint, ION, Oncology Supply and Medical Initiatives consolidated their results into one financial statement. Oncology Supply could allegedly sell a drug below its acquisition cost and recover the loss through the manufacturer’s administration fee paid to ION. A distributor’s invoice could show a loss while the same sale made money elsewhere in the group.

A Pharmacy Name on a Repackaging Operation

The whistleblower alleged that Medical Initiatives presented itself as a pharmacy while doing the work of a commercial drug repackager. The government alleged the same thing: that the “pharmacy” was in reality a repackaging operation that created and shipped millions of prefilled syringes to oncology practices, breaking the sterility of the original vials and pooling their contents. According to the complaint, it did not fill individual patient prescriptions. It sold prefilled syringes in bulk to wholesalers for resale to healthcare providers.

The complaint alleged that Medical Initiatives avoided Food and Drug Administration registration for its repackaging activities, used commercial extraction equipment and produced syringes without valid prescriptions. It also alleged that no supplemental application had been filed for the new drug presentations. These allegations went directly to what happened after the original manufacturer supplied an approved vial.

The quality concerns followed the same physical steps as the profit. The complaint alleged that pooling contents from different vials interfered with labeling, lot control and traceability, and created a risk of cross-contamination. It also alleged that the facility lacked operating procedures consistent with manufacturing and repackaging. The government alleged that the company never submitted safety, stability or sterility data to the Food and Drug Administration, and that at times the syringes were prepared in nonsterile conditions, contaminated with bacteria and other unknown particles, and lacked the required quality and purity. The people receiving the syringes were cancer patients, and the alleged gaps concerned the handling of the medicine reaching them.

The Product Code Had to Follow the Package

The complaint alleged that the prefilled syringes had no valid National Drug Codes of their own. It connected that missing product identity to both tracking the drug and the accuracy of claims containing a drug code. The original manufacturer’s vial and the repackager’s syringe were different presentations of the medicine.

The pricing significance of that distinction appears in Examining the Value of Pharmacy Benefit Management Companies, a 2004 commentary in the American Journal of Health-System Pharmacy. In its discussion of mail-order pharmacies, the paper described how a licensed repackager could buy medicine in bulk, divide it into smaller packages and assign the repackaged product a new National Drug Code with its own average wholesale price. Its example showed how a larger advertised discount could still leave the payer paying more when the underlying benchmark changed.

That paper explains a different repackaging business, but it identifies why package identity matters to payment. Here, the whistleblower alleged missing codes and missing price reports for the new syringes. A review confined to the familiar drug name would miss the intermediate business that changed the container, extracted the extra product and set the new selling price.

Overfill as a Sales Pitch in Another Oncology Case

The whistleblower cases resolved in Amgen’s 2012 civil settlement also alleged that overfill became a selling point for physician profit. A whistleblower’s amended complaint against Amgen alleged that extra drug in Aranesp, Epogen and Neupogen vials created additional billable profit for providers. It also alleged that sales representatives used profit spreadsheets to persuade providers to buy the drugs and were told not to leave those spreadsheets in practices or retain them on their computers.

The shared commercial idea is the provider’s margin. In the AmerisourceBergen complaint, extraction and repackaging allegedly let the distributor share the overfill benefit through a syringe price. In the Amgen complaint, sales staff allegedly sold the prescribing decision on the profit the provider could earn. In each account, what the sales team said about reimbursement helps explain why the customer would buy.

The Civil Settlement and Whistleblower Award

The AmerisourceBergen civil settlement resolved allegations from three separate whistleblower actions under the False Claims Act. One came from a former chief operating officer of AmerisourceBergen Specialty Group, whose amended complaint supplies the operational account above. A healthcare company brought another action. Two individual whistleblowers brought the third against AmerisourceBergen Drug Corporation.

The government alleged that the company caused false claims to the Centers for Medicare and Medicaid Services, TRICARE, the Federal Employees Health Benefits Program and the Department of Veterans Affairs. The Justice Department’s announcement allocated $581,809,006 to the federal government and $43,190,994 to state Medicaid programs. The announced whistleblower award from the federal portion was about $93 million, collectively.

A whistleblower case under the False Claims Act can pay 15% to 30% of what the government recovers.

The resolution also brought a five-year corporate integrity agreement.

What Evidence Is Needed to Prove Fraud?

For an oncology repackaging case, the useful evidence connects what entered the facility, what left it, what the customer paid and what the government reimbursed. The AmerisourceBergen complaint makes those connections concrete through extraction equipment, transfers between affiliated businesses, syringe pricing, purchasing fees, product codes and omitted price reports.

An employee familiar with production may understand why the syringe output exceeds the labeled quantity purchased. Someone in sales or contracting may know how that output funds the customer’s discount. A quality or reimbursement specialist may recognize that the product identifier or reported price no longer describes what the business supplied. Those perspectives concern different parts of the transaction, and we work with the insider to connect them.

The alleged arrangement put revenue into the gaps between those functions. Following the drug through the facility and following the money through the corporate group brings the same sale back into view.

You Know How the Syringes Became Revenue

If you know how an oncology business turns vial contents into syringes, discounts and government bills, talk with our whistleblower experts. We work with you to build your strongest pharmaceutical whistleblower case, bring in pharmaceutical fraud whistleblower lawyers who know drug repackaging and Medicare reimbursement, and stay beside you at every step.